Pipeline

Five things for pharma marketers to know: Friday, December 9, 2016

Five things for pharma marketers to know: Friday, December 9, 2016

By

BMS to pay $19.5 million to settle marketing violations for Abilify; AstraZeneca to cut 700 U.S. jobs; Trump reportedly considering Jim O'Neill to lead FDA

MM&M's top 5 stories in November 2016

MM&M's top 5 stories in November 2016

By

How VR, nanotechnology, and 3D printing could improve the value of healthcare; 100 experimental therapies in late-stage clinical trials; Kite Pharma plans "controlled" launch of CAR-T therapy

The 2017 pipeline report: What to know about next year's launches

The 2017 pipeline report: What to know about next year's launches

By

Here's a look at 100 experimental therapies in late-stage clinical trials.

Five things for pharma marketers to know: Wednesday, November 23, 2016

Five things for pharma marketers to know: Wednesday, November 23, 2016

By

Lilly's experimental Alzheimer's drug fails in another trial; two more patients die during trial for Juno's CAR-T therapy; NEJM launches platform in China

Five things for pharma marketers to know: Tuesday, November 22, 2016

Five things for pharma marketers to know: Tuesday, November 22, 2016

By

Intarcia submits diabetes drug-delivery pump for FDA approval; Shire to build rare-disease innovation hub; AstraZeneca to resume durvalumab trials

Five things for pharma marketers to know: Monday, November 21, 2016

Five things for pharma marketers to know: Monday, November 21, 2016

By

Novartis to delay clinical trials of contact lens for diabetes patients; the ADA calls for hearings on insulin pricing; Vice launches healthcare channel

Merck's Keytruda wins approval in first-line lung cancer

Merck's Keytruda wins approval in first-line lung cancer

By

Keytruda is the first immuno-oncology drug approved to treat first-line lung cancer.

New science drives biopharma interest in neurological conditions

New science drives biopharma interest in neurological conditions

By

The neurology market is again attracting attention and investment from various — and at times unexpected — corners of the biopharma industry.

Five things for pharma marketers to know: Tuesday, October 11, 2016

Five things for pharma marketers to know: Tuesday, October 11, 2016

By

Opdivo fails in lung cancer trial; hedge fund sues Theranos; Takeda and Crescendo partner to develop humabody-based therapies

Drugmakers set their sights on the next potential blockbuster disease: NASH

Drugmakers set their sights on the next potential blockbuster disease: NASH

By

A race has emerged in a new disease space estimated to be worth billions of dollars.

Five things for pharma marketers to know: Tuesday, September 13, 2016

Five things for pharma marketers to know: Tuesday, September 13, 2016

By

Drugmakers routinely pay ghostwriters to write industry-funded research articles; Horizon to buy Raptor for $800 million; WellDoc partners with J&J

Five things for pharma marketers to know: Thursday, September 1, 2016

Five things for pharma marketers to know: Thursday, September 1, 2016

By

Novartis to fold its cell and gene therapy business; Novo Nordisk CEO to retire; the FDA issues a safety warning for opioids taken with anti-anxiety drugs

How About a Moon Shot for Orphan Diseases?

How About a Moon Shot for Orphan Diseases?

You can see it everywhere: on TV and in newspapers and ads. The decades of struggle against cancer are paying off.

Drugmakers revive R&D focus on long stagnant women's health market

Drugmakers revive R&D focus on long stagnant women's health market

By

Fueled by innovation in new treatments, the underserved women's health market has begun to turn the proverbial corner. What took it so long?

Long neglected, the osteoporosis market prepares for new entrants

Long neglected, the osteoporosis market prepares for new entrants

By

The osteoporosis drug market is bracing for the advent of potentially game-changing treatments.

Bolstered by new data, Radius Health focuses on unmet needs in the osteoporosis market

Bolstered by new data, Radius Health focuses on unmet needs in the osteoporosis market

By

Only one new osteoporosis drug has been approved over the last six years.

Opdivo bet backfires, creates opening for Merck to pursue DTC

Opdivo bet backfires, creates opening for Merck to pursue DTC

By

A massive disappointment for Bristol-Myers Squibb's Opdivo in first-line lung cancer has leveled the playfield for Merck's Keytruda.

Five things for pharma marketers to know: Friday, August 5, 2016

Five things for pharma marketers to know: Friday, August 5, 2016

By

Opdivo fails to meet endpoint in new lung cancer patients; abuse-deterrent drug gets nod from FDA panel; Cephalon settles pay-for-delay case

As immuno-oncology therapies evolve, so will the marketing

As immuno-oncology therapies evolve, so will the marketing

By

Interest in oncology is on the rise as the blockbuster drug era breathes its last, and this has altered marketing in cancer care.

Top 25 oncology products in 2015

Top 25 oncology products in 2015

Despite the arrivals of new drugs, Genentech continues to be the market leader. Its drugs, Rituxan, Avastin, and Herceptin, are the category leaders, generating a total of $9.29 billion in sales.

CAR-T therapies: the future of cancer care, or an industry pipe dream?

CAR-T therapies: the future of cancer care, or an industry pipe dream?

By

While analysts predict a first-in-class appearance before the FDA by 2018, many obstacles have arisen.

Five things for pharma marketers to know: Friday, July 22, 2016

Five things for pharma marketers to know: Friday, July 22, 2016

By

Herceptin biosimilar meets endpoint in clinical trial; Roche plans to launch five new drugs over the next year; government seeks to block insurer deals

Five things for pharma marketers to know: Monday, July 18, 2016

Five things for pharma marketers to know: Monday, July 18, 2016

By

Roche's blood cancer drug fails to meet trial goal; the FDA says Valeant's psoriasis drug carries risk of suicide; Facebook tests disappearing messages

Five things for pharma marketers to know: Wednesday, June 29, 2016

Five things for pharma marketers to know: Wednesday, June 29, 2016

By

GIlead Sciences' new HCV treatment receives approval; FDA adcomm votes in favor of Jardiance health-outcomes' claims; FDA names head of new oncology center

Five things for pharma marketers to know: Tuesday, June 28, 2016

Five things for pharma marketers to know: Tuesday, June 28, 2016

By

Opdivo nets sixth Breakthrough Therapy designation; AstraZeneca seeks rare indication to block Crestor generics; Endo mulls sale to reduce debt

New first-line lung data is positive for Merck's Keytruda, but competitor looms large

New first-line lung data is positive for Merck's Keytruda, but competitor looms large

By

A trial studying Keytruda met its endpoint in first-line lung cancer patients.

Five things for pharma marketers to know: Monday, June 13, 2016

Five things for pharma marketers to know: Monday, June 13, 2016

By By

A new Sanofi combination diabetes drug meets clinical trial targets; IBM partners with the American Diabetes Association; Dr. Reddy's to buy eight Teva drugs

Bristol-Myers Squibb's Yervoy, Opdivo combo data confers edge in lung cancer

Bristol-Myers Squibb's Yervoy, Opdivo combo data confers edge in lung cancer

By

Investors said a combination of Opdivo and Yervoy is the top-performing regimen in a niche of non-small cell lung-cancer patients.

ASCO 2016 Preview: Expect data on CDK inhibitors, CAR-T therapies, and pricing

ASCO 2016 Preview: Expect data on CDK inhibitors, CAR-T therapies, and pricing

By

Competition among new breast cancer drugs, an immunotherapy contender, and pricing discussions headline one of the biggest cancer conferences of the year.

Merck educates doctors about biosimilars, long before it will sell one in the U.S.

Merck educates doctors about biosimilars, long before it will sell one in the U.S.

By

Drugmakers like Merck are making a big education push as they lay the groundwork for future biosimilars.

OPINION

Email Newsletters